Acumen Pharmaceuticals Hosting Conference Call Covering Positive Topline Results from Phase 1 Study of ACU193 for Early Alzheimer’s Disease

(24/7 MARKET NEWS) – Acumen Pharmaceuticals, Inc. (NADAQ: ABOS) states, this morning, that it is hosting a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD.

Acumen Pharmaceuticals is trading at $8.75, up $2.47 (+39.33%), on 1.84M premarket shares traded.

Its 52-week range is $3.52 to $10.97. This morning’s high is $9.82 and the only thing between its current price and a new 52-high is some resistance from late October and early November.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.